Patients Treated With Risperidone Long Acting Injection Had A Significantly Longer Time To Relapse Compared To Quetiapine In Clinical Study

Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms (1,2). Today, data from a new international study showed that patients treated with risperidone long-acting injection (RLAI) had a significantly longer time to relapse (3) compared to patients treated with an oral atypical medication, quetiapine.

More: continued here

Filed under: Schizophrenia on May 15th, 2008